Kerala cannot continue to procure the original molecule at high prices when an approved generic formulation is available at a fraction of the price, says B. Ekbal
Spinal Muscular Atrophy drug: regulatory approval should guide Kerala’s procurement policy, say experts
Kerala cannot continue to procure the original molecule at high prices when an approved generic formulation is available at a fraction of the price, says B. Ekbal
Published: 26 June 2026
This article was originally published by an external source. Read the full story at the source.
Read Full Article at Source ↗